These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37162602)

  • 1. Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
    Karaboyun K; Cavdar E; Irıagac Y; Celebı A; Kapagan T; Gulturk I; Demır O; Avcı O; Seber ES
    Support Care Cancer; 2023 May; 31(6):330. PubMed ID: 37162602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy.
    Stahlschmidt R; Ferracini AC; Medeiros LM; Souza CM; Juliato CRT; Mazzola PG
    Rev Bras Ginecol Obstet; 2020 Nov; 42(11):726-730. PubMed ID: 33254267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
    Bui KT; Willson ML; Goel S; Beith J; Goodwin A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis.
    Landi SN; Doll KM; Bensen JT; Hendrix L; Anders CK; Wu JM; Nichols HB
    Cancer Causes Control; 2016 Nov; 27(11):1325-1332. PubMed ID: 27680018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase Inhibitors Are Associated With Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study.
    Robinson PJ; Bell RJ; Christakis MK; Ivezic SR; Davis SR
    J Sex Med; 2017 Dec; 14(12):1566-1574. PubMed ID: 29066307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The feasibility of pelvic floor training to treat urinary incontinence in women with breast cancer: a telehealth intervention trial.
    Colombage UN; Soh SE; Lin KY; Kruger J; Frawley HC
    Breast Cancer; 2023 Jan; 30(1):121-130. PubMed ID: 36163601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy.
    Akyol M; Alacacioglu A; Demir L; Kucukzeybek Y; Yildiz Y; Gumus Z; Kara M; Salman T; Varol U; Taskaynatan H; Oflazoglu U; Bayoglu V; Tarhan MO
    Cancer Biomark; 2017; 18(4):441-449. PubMed ID: 28106545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer.
    Basmadjian RB; Lupichuk S; Xu Y; Quan ML; Cheung WY; Brenner DR
    JAMA Netw Open; 2024 Mar; 7(3):e242082. PubMed ID: 38477918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of use of the International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI-SF) for impairment rating: a transversal retrospective study of 120 patients.
    Timmermans L; Falez F; Mélot C; Wespes E
    Neurourol Urodyn; 2013 Sep; 32(7):974-9. PubMed ID: 23281067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study on de novo postoperative urinary incontinence after pelvic organ prolapse surgery.
    Ugianskiene A; Kjærgaard N; Inger Lindquist AS; Larsen T; Glavind K
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():10-14. PubMed ID: 29024913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
    Pagani O; Regan MM; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Perez EA; Ciruelos E; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Pinotti G; Puglisi F; Crivellari D; Ruhstaller T; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Bernhard J; Luo W; Ribi K; Viale G; Coates AS; Gelber RD; Goldhirsch A; Francis PA; ;
    N Engl J Med; 2014 Jul; 371(2):107-18. PubMed ID: 24881463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.